Read-Gene S.A. (WSE:RDG)

Poland flag Poland · Delayed Price · Currency is PLN
5.06
0.00 (0.00%)
Last updated: May 25, 2026, 10:25 AM CET
Market Cap59.66M +16.6%
Revenue (ttm)15.57M +17.7%
Net Income808.33K
EPS0.07
Shares Out 11.79M
PE Ratio73.80
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44
Open5.06
Previous Close5.06
Day's Range5.06 - 5.06
52-Week Range3.92 - 6.90
Beta0.30
Analystsn/a
Price Targetn/a
Earnings DateMay 13, 2026

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It ... [Read more]

Industry Biotechnology & Medical Research
Sector Healthcare
Founded 2005
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RDG
Full Company Profile

Financial Performance

Financial Statements